Evidence map›Paper›PMID 37864723›Full record

ArticleEuropean journal of clinical pharmacology2023

Buprenorphine plasma and cerebrospinal fluid concentrations in osteoarthritis patients during low-dose transdermal patch dosing.

Lasse Härkänen, Henriikka Hakomäki, Jukka Huopio, Hannu Kokki, Sanni Korhonen, Marko Lehtonen, Sari Sjövall, Merja Kokki

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Lasse Härkänen *School of Medicine, University of Eastern Finland, Kuopio, Finland.
Henriikka Hakomäki *School of Pharmacy, University of Eastern Finland, Kuopio, Finland. henriikka.hakomaki@uef.fi.
Jukka HuopioDepartment of Orthopedic Surgery, Kuopio University Hospital, Kuopio, Finland.
Hannu KokkiSchool of Medicine, University of Eastern Finland, Kuopio, Finland.
Sanni KorhonenSchool of Pharmacy, University of Eastern Finland, Kuopio, Finland.
Marko LehtonenSchool of Pharmacy, University of Eastern Finland, Kuopio, Finland.
Sari SjövallDepartment of Anestesia, Satakunta Central Hospital, Pori, Finland.
Merja KokkiDepartment of Anesthesia and Intensive Care, Kuopio University Hospital, Kuopio, Finland.
University of Eastern Finland · FIKuopio University Hospital · FISatakunta Central Hospital · FI

Funding

Northern Savo Hospital District 5070244
6 · The paper itself

Abstract

methodsFifty-six (56) patients scheduled for arthroplasty, received 7-day extended-release buprenorphine transdermal patches (5 µg/h) for five consecutive weeks, starting two weeks prior to the surgery. Simultaneous plasma and cerebrospinal fluid (CSF) samples were collected during spinal anesthesia.

resultsMedian buprenorphine plasma and CSF concentrations at steady-state were 54 pg/mL (range 8.6 - 167 pg/mL) and 1.6 pg/mL (0.30 - 7.3 pg/mL), respectively. The median CSF/plasma -ratio was 3% (range 0.35 - 16%). Large between-subject variability was observed in the measured buprenorphine concentrations within the study population.

Indexed as

BuprenorphineOsteoarthritisAdministration, CutaneousAnalgesics, OpioidHumansTransdermal PatchAnalgesics, OpioidBuprenorphineBuprenorphineCerebrospinal fluidPlasmaTransdermal

Identifiers

PMID37864723
PMCPMC10663223
OpenAlexW4387844716

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.